Anika Therapeutics Inc has a consensus price target of $26.25, established from looking at the 14 latest analyst ratings. The last 3 analyst ratings were released from Barrington Research, Stephens & Co., and Barrington Research on March 14, 2024, March 14, 2024, and January 3, 2024. With an average price target of $29.33 between Barrington Research, Stephens & Co., and Barrington Research, there's an implied 14.18% upside for Anika Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/14/2024 | ANIK | Buy Now | Anika Therapeutics | $25.69 | 44.02% | Barrington Research | Michael Petusky | $29 → $37 | Maintains | Outperform | Get Alert |
03/14/2024 | ANIK | Buy Now | Anika Therapeutics | $25.69 | -14.36% | Stephens & Co. | George Sellers | → $22 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
01/03/2024 | ANIK | Buy Now | Anika Therapeutics | $25.69 | 12.88% | Barrington Research | Michael Petusky | $28 → $29 | Maintains | Outperform | Get Alert |
11/03/2023 | ANIK | Buy Now | Anika Therapeutics | $25.69 | 8.99% | Barrington Research | Michael Petusky | $24 → $28 | Maintains | Outperform | Get Alert |
08/14/2023 | ANIK | Buy Now | Anika Therapeutics | $25.69 | -6.58% | Barrington Research | Michael Petusky | → $24 | Upgrade | Market Perform → Outperform | Get Alert |
08/10/2023 | ANIK | Buy Now | Anika Therapeutics | $25.69 | -10.47% | Stephens & Co. | George Sellers | $28 → $23 | Maintains | Equal-Weight | Get Alert |
05/31/2023 | ANIK | Buy Now | Anika Therapeutics | $25.69 | 8.99% | Stephens & Co. | George Sellers | → $28 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
04/14/2023 | ANIK | Buy Now | Anika Therapeutics | $25.69 | 8.99% | Stephens & Co. | George Sellers | → $28 | Reiterates | → Equal-Weight | Get Alert |
03/07/2023 | ANIK | Buy Now | Anika Therapeutics | $25.69 | — | Barrington Research | Michael Petusky | — | Downgrade | Outperform → Market Perform | Get Alert |
11/09/2022 | ANIK | Buy Now | Anika Therapeutics | $25.69 | 20.67% | Barrington Research | Michael Petusky | → $31 | Upgrade | Market Perform → Outperform | Get Alert |
10/14/2022 | ANIK | Buy Now | Anika Therapeutics | $25.69 | 1.21% | Stephens & Co. | George Sellers | → $26 | Reinstates | → Equal-Weight | Get Alert |
03/09/2022 | ANIK | Buy Now | Anika Therapeutics | $25.69 | — | Stephens & Co. | Chris Cooley | — | Downgrade | Overweight → Equal-Weight | Get Alert |
11/16/2021 | ANIK | Buy Now | Anika Therapeutics | $25.69 | 114.09% | Stephens & Co. | Chris Cooley | — | Initiates | → Overweight | Get Alert |
07/16/2021 | ANIK | Buy Now | Anika Therapeutics | $25.69 | 79.06% | UBS | — | — | Initiates | → Neutral | Get Alert |
The latest price target for Anika Therapeutics (NASDAQ: ANIK) was reported by Barrington Research on March 14, 2024. The analyst firm set a price target for $37.00 expecting ANIK to rise to within 12 months (a possible 44.02% upside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for Anika Therapeutics (NASDAQ: ANIK) was provided by Barrington Research, and Anika Therapeutics maintained their outperform rating.
The last upgrade for Anika Therapeutics Inc happened on August 14, 2023 when Barrington Research raised their price target to $24. Barrington Research previously had a market perform for Anika Therapeutics Inc.
The last downgrade for Anika Therapeutics Inc happened on March 7, 2023 when Barrington Research changed their price target from N/A to N/A for Anika Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anika Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anika Therapeutics was filed on March 14, 2024 so you should expect the next rating to be made available sometime around March 14, 2025.
While ratings are subjective and will change, the latest Anika Therapeutics (ANIK) rating was a maintained with a price target of $29.00 to $37.00. The current price Anika Therapeutics (ANIK) is trading at is $25.69, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.